Cargando…
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials
OBJECTIVES: The objective of this systematic review was to provide an overview of current developments and potentially available therapeutic options for spondyloarthritis (SpA) in the coming years. METHODS: We conducted a systematic review of 17 national and international clinical trial databases fo...
Autores principales: | Denis, Agathe, Sztejkowski, Cédric, Arnaud, Laurent, Becker, Guillaume, Felten, Renaud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387652/ https://www.ncbi.nlm.nih.gov/pubmed/37507210 http://dx.doi.org/10.1136/rmdopen-2023-003279 |
Ejemplares similares
-
Development of a web-based decision aid for initiating biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in axial spondyloarthritis
por: Beckers, Esther, et al.
Publicado: (2023) -
Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference
por: Sepriano, Alexandre, et al.
Publicado: (2021) -
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
por: Marona, Jose, et al.
Publicado: (2020) -
Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review
por: Navarro-Compán, Victoria, et al.
Publicado: (2017) -
Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study
por: López-Medina, Clementina, et al.
Publicado: (2021)